The role of cytokines/chemokines in the pathogenesis of atopic dermatitis

Current Problems in Dermatology

Volumn 41, Issue , 2011, Pages 80-92

  Yamanaka, Kei Ichi ^a   Mizutani, Hitoshi ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; BCG VACCINE; CHEMOKINE; CYTOKINE; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 31; INTERLEUKIN 4; MESSENGER RNA; OMALIZUMAB; RITUXIMAB; THYMIC STROMAL LYMPHOPOIETIN;

ARTICLE; ATOPIC DERMATITIS; BCG VACCINATION; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; STAPHYLOCOCCUS INFECTION; TH1 CELL; TH1 TH2 BALANCE; TH17 CELL; TH2 CELL;

ANIMALS; CHEMOKINES; CYTOKINES; DERMATITIS, ATOPIC; HUMANS; IMMUNOTHERAPY; MICE; MODELS, IMMUNOLOGICAL; STAPHYLOCOCCAL INFECTIONS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TH2 CELLS;

EID: 79958048280     PISSN: 14215721     EISSN: 16622944     Source Type: Book Series    
DOI: 10.1159/000323299     Document Type: Article

References (82)

1. Del Prete G: Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy. Allergy 1992;47:450-455.
2. Kaminishi K, Soma Y, Kawa Y, Mizoguchi M: Flow cytometric analysis of IL-4, IL-13 and IFN-gamma expression in peripheral blood mononuclear cells and detection of circulating IL-13 in patients with atopic dermatitis provide evidence for the involvement of type 2 cytokines in the disease. J Dermatol Sci 2002;29:19-25. (Pubitemid 34462188)
3. Metwally SS, Mosaad YM, Abdel-Samee ER, El-Gayyar MA, Abdel-Aziz AM, El-Chennawi FA: IL-13 gene expression in patients with atopic dermatitis: relation to IgE level and to disease severity. Egypt J Immunol 2004;11:171-177.
4. Grewe M, Gyufko K, Schopf E, Krutmann J: Lesional expression of interferon-gamma in atopic eczema. Lancet 1994;343:25-26.
5. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y: Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 2008;128: 2625-2630.
6. Wuthrich B, Schmid-Grendelmeier P: The atopic eczema/dermatitis syndrome: epidemiology, natural course, and immunology of the IgE-associated ('extrinsic') and the nonallergic ('intrinsic') AEDS. J Investig Allergol Clin Immunol 2003;13:1-5. (Pubitemid 36781516)
7. Bieber T: Atopic dermatitis. Ann Dermatol 2010;22: 125-137.
8. Miraglia del Giudice M, Decimo F, Leonardi S, et al: Immune dysregulation in atopic dermatitis. Allergy Asthma Proc 2006;27:451-455. (Pubitemid 44916009)
9. Wollenberg A, Kraft S, Hanau D, Bieber T: Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol 1996;106:446-453. (Pubitemid 26117582)
10. Novak N, Bieber T. The role of dendritic cell subtypes in the pathophysiology of atopic dermatitis. J Am Acad Dermatol 2005;53:S171-S176. (Pubitemid 40966763)
11. Barnes PJ: Role of GATA-3 in allergic diseases. Curr Mol Med 2008;8:330-334.
12. Ziegler SF, Artis D: Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol 2010;11: 289-293.
13. Soumelis V, Reche PA, Kanzler H, et al: Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002;3:673-680. (Pubitemid 34752477)
14. Pandey A, Ozaki K, Baumann H, et al: Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin. Nat Immunol 2000;1:59-64.
15. Park LS, Martin U, Garka K, et al: Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: formation of a functional heteromeric complex requires interleukin 7 receptor. J Exp Med 2000;192:659-670.
16. Allakhverdi Z, Comeau MR, Jessup HK, et al: Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med 2007;204:253-258. (Pubitemid 46294541)
17. Bogiatzi SI, Fernandez I, Bichet JC, et al: Cutting edge: proinflammatory and Th2 cytokines synergize to induce thymic stromal lymphopoietin production by human skin keratinocytes. J Immunol 2007; 178:3373-3377. (Pubitemid 46417601)
18. Jung T, Stingl G: Atopic dermatitis: therapeutic concepts evolving from new pathophysiologic insights. J Allergy Clin Immunol 2008;122:1074-1081.
19. Wang YH, Angkasekwinai P, Lu N, et al: IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J Exp Med 2007;204:1837-1847. (Pubitemid 47236321)
20. Soumelis V, Liu YJ: Human thymic stromal lymphopoietin: a novel epithelial cell-derived cytokine and a potential key player in the induction of allergic inflammation. Springer Semin Immunopathol 2004;25:325-333. (Pubitemid 38296940)
21. Liu YJ: Thymic stromal lymphopoietin: master switch for allergic inflammation. J Exp Med 2006; 203:269-273.
22. Dillon SR, Sprecher C, Hammond A, et al: Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004;5:752-760. (Pubitemid 39023308)
23. Bilsborough J, Leung DY, Maurer M, et al: IL-31 is associated with cutaneous lymphocyte antigenpositive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol 2006;117: 418-425. (Pubitemid 43190155)
24. Sonkoly E, Muller A, Lauerma AI, et al: IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006;117: 411-417. (Pubitemid 43192023)
25. Raap U, Wichmann K, Bruder M, et al: Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol 2008;122:421-423.
26. Iikura M, Suto H, Kajiwara N, et al: IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 2007;87:971-978. (Pubitemid 47429189)
27. Liew FY, Pitman NI, McInnes IB: Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010;10:103-110.
28. Simon D, von Gunten S, Borelli S, Braathen LR, Simon HU: The interleukin-13 production by peripheral blood T cells from atopic dermatitis patients does not require CD2 costimulation. Int Arch Allergy Immunol 2003;132:148-155. (Pubitemid 37409846)
29. Hamid Q, Boguniewicz M, Leung DY: Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994;94: 870-876. (Pubitemid 24251022)
30. Kosaka H, Yoshimoto T, Fujimoto J, Nakanishi K: Interferon-gamma is a therapeutic target molecule for prevention of postoperative adhesion formation. Nat Med 2008;14:437-441. (Pubitemid 351499387)
31. Jin H, Kumar L, Mathias C, et al: Toll-like receptor 2 is important for the T(H)1 response to cutaneous sensitization. J Allergy Clin Immunol 2009;123: 875-882.
32. Butcher EC, Picker LJ: Lymphocyte homing and homeostasis. Science 1996;272:60-66. (Pubitemid 26110755)
33. Campbell JJ, Butcher EC: Chemokines in tissuespecific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 2000;12: 336-341. (Pubitemid 30240545)
34. Narbutt J, Lesiak A, Sysa-Jedrzeiowska A, et al: The imbalance in serum concentration of Th-1-and Th-2-derived chemokines as one of the factors involved in pathogenesis of atopic dermatitis. Mediators Inflamm 2009;2009:269541.
35. Park CO, Lee HJ, Lee JH, et al: Increased expression of CC chemokine ligand 18 in extrinsic atopic dermatitis patients. Exp Dermatol 2008;17:24-29. (Pubitemid 350269208)
36. Imai T, Yoshida T, Baba M, Nishimura M, Kakizaki M, Yoshie O: Molecular cloning of a novel T celldirected CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector. J Biol Chem 1996;271:21514-21521. (Pubitemid 26293018)
37. Imai T, Baba M, Nishimura M, Kakizaki M, Takagi S, Yoshie O: The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem 1997;272: 15036-15042. (Pubitemid 27251781)
38. Vulcano M, Albanesi C, Stoppacciaro A, et al: Dendritic cells as a major source of macrophagederived chemokine/CCL22 in vitro and in vivo. Eur J Immunol 2001;31:812-822. (Pubitemid 32241777)
39. Kakinuma T, Nakamura K, Wakugawa M, et al: Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activationregulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001;107: 535-541. (Pubitemid 32210037)
40. Kakinuma T, Nakamura K, Wakugawa M, et al: Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis. Clin Exp Immunol 2002;127: 270-273. (Pubitemid 34233932)
41. Shimada Y, Takehara K, Sato S: Both Th2 and Th1 chemokines (TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis. J Dermatol Sci 2004;34:201-208. (Pubitemid 38543003)
42. Nakazato J, Kishida M, Kuroiwa R, Fujiwara J, Shimoda M, Shinomiya N: Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis. Pediatr Allergy Immunol 2008;19: 605-613.
43. Nakayama T, Fujisawa R, Yamada H, et al: Inducible expression of a CC chemokine liver-and activationregulated chemokine (LARC)/macrophage inflammatory protein (MIP)-3 alpha/CCL20 by epidermal keratinocytes and its role in atopic dermatitis. Int Immunol 2001;13:95-103. (Pubitemid 32060981)
44. Vanbervliet B, Homey B, Durand I, et al: Sequential involvement of CCR2 and CCR6 ligands for immature dendritic cell recruitment: possible role at inflamed epithelial surfaces. Eur J Immunol 2002;32: 231-242. (Pubitemid 34092841)
45. Oyama T, Miura S, Watanabe C, et al: CXCL12 and CCL20 play a significant role in mucosal T-lymphocyte adherence to intestinal microvessels in mice. Microcirculation 2007;14:753-766. (Pubitemid 47434290)
46. Nomura I, Gao B, Boguniewicz M, Darst MA, Travers JB, Leung DY: Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analysis. J Allergy Clin Immunol 2003;112:1195-1202. (Pubitemid 37550015)
47. Schmuth M, Neyer S, Rainer C, et al: Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with impaired permeability barrier function. Exp Dermatol 2002;11:135-142. (Pubitemid 36934631)
48. Schon MP, Zollner TM, Boehncke WH: The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders. J Invest Dermatol 2003;121: 951-962. (Pubitemid 37430959)
49. Tsutsui H, Yoshimoto T, Hayashi N, Mizutani H, Nakanishi K: Induction of allergic inflammation by interleukin-18 in experimental animal models. Immunol Rev 2004;202:115-138. (Pubitemid 39576909)
50. Yoshimoto T, Tsutsui H, Tominaga K, et al: IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci USA 1999;96: 13962-13966.
51. Yoshimoto T, Mizutani H, Tsutsui H, et al: IL-18 induction of IgE: dependence on CD4+ T cells, IL-4 and STAT6. Nat Immunol 2000;1:132-137.
52. Omoto Y, Tokime K, Yamanaka K, et al: Human mast cell chymase cleaves pro-IL-18 and generates a novel and biologically active IL-18 fragment. J Immunol 2006;177:8315-8319. (Pubitemid 44893792)
53. Mihm MC Jr, Soter NA, Dvorak HF, Austen KF: The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 1976;67:305-312.
54. Omoto Y, Yamanaka K, Tokime K, et al: Granzyme B is a novel interleukin-18 converting enzyme. J Dermatol Sci 2010;59:129-135.
55. Nakanishi K, Tsutsui H, Yoshimoto T: Importance of IL-18-induced super Th1 cells for the development of allergic inflammation. Allergol Int 2010;59: 137-141.
56. Hamasaki T, Hashiguchi S, Ito Y, et al: Human antihuman IL-18 antibody recognizing the IL-18-binding site 3 with IL-18 signaling blocking activity. J Biochem 2005;138:433-442. (Pubitemid 41703695)
57. Howell MD, Boguniewicz M, Pastore S, et al: Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol 2006;121:332-338. (Pubitemid 44768007)
58. Miller LS, O'Connell RM, Gutierrez MA, et al: MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity 2006;24: 79-91. (Pubitemid 43077202)
59. Terada M, Tsutsui H, Imai Y, et al: Contribution of IL-18 to atopic-dermatitis-like skin inflammation induced by Staphylococcus aureus product in mice. Proc Natl Acad Sci USA 2006;103:8816-8821. (Pubitemid 43878102)
60. Akdis CA, Akdis M: Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol 2009;123:735-746, quiz 47-48.
61. Toda M, Leung DY, Molet S, et al: Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol 2003; 111:875-881. (Pubitemid 36470263)
62. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, et al: Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 2008;181:7420-7427.
63. Boniface K, Diveu C, Morel F, et al: Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation. J Immunol 2007;178:4615-4622. (Pubitemid 46492414)
64. Nograles KE, Zaba LC, Shemer A, et al: IL-22-producing 'T22' T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 2009;123:1244-1252.
65. Yamanaka K, Yuta A, Kakeda M, et al: Induction of IL-10-producing regulatory T cells with TCR diversity by epitope-specific immunotherapy in pollinosis. J Allergy Clin Immunol 2009;124: 842-845.
66. Szegedi A, Barath S, Nagy G, et al: Regulatory T cells in atopic dermatitis: epidermal dendritic cell clusters may contribute to their local expansion. Br J Dermatol 2009;160:984-993.
67. Yamanaka K, Tanaka M, Tsutsui H, et al: Skinspecific caspase-1-transgenic mice show cutaneous apoptosis and pre-endotoxin shock condition with a high serum level of IL-18. J Immunol 2000;165: 997-1003. (Pubitemid 30484769)
68. Kitagawa H, Yamanaka K, Kakeda M, et al: Propionibacterium acnes vaccination induces regulatory T cells and Th1 immune responses and improves mouse atopic dermatitis. Exp Dermatol, in press.
69. Mori H, Yamanaka K, Matsuo K, Kurokawa I, Yasutomi Y, Mizutani H: Administration of Ag85B showed therapeutic effects to Th2-type cytokinemediated acute phase atopic dermatitis by inducing regulatory T cells. Arch Dermatol Res 2009;301: 151-157.
70. Tokura Y: Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci 2010;58:1-7.
71. Phipps S, Flood-Page P, Menzies-Gow A, Ong YE, Kay AB: Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J Invest Dermatol 2004;122:1406-1412. (Pubitemid 38757222)
72. Oldhoff JM, Darsow U, Werfel T, et al: No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int Arch Allergy Immunol 2006;141:290-294. (Pubitemid 44597748)
73. Oldhoff JM, Darsow U, Werfel T, et al: Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005;60:693-696. (Pubitemid 40562479)
74. Simon D, Wittwer J, Kostylina G, Buettiker U, Simon HU, Yawalkar N: Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol 2008;122:423-424.
75. Moul DK, Routhouska SB, Robinson MR, Korman NJ: Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2008;58:984-989.
76. Takiguchi R, Tofte S, Simpson B, et al: Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2007;56:222-227. (Pubitemid 46074243)
77. Simon D, Hosli S, Kostylina G, Yawalkar N, Simon HU: Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008;121: 122-128.
78. Kruse N, Tony HP, Sebald W: Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement. EMBO J 1992;11: 3237-3244.
79. Kruse N, Shen BJ, Arnold S, Tony HP, Muller T, Sebald W. Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation. EMBO J 1993;12:5121-5129. (Pubitemid 23358502)
80. Tony HP, Shen BJ, Reusch P, Sebald W: Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency. Eur J Biochem 1994;225:659-665. (Pubitemid 24325584)
81. Zurawski SM, Vega F Jr, Huyghe B, Zurawski G: Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J 1993;12: 2663-2670. (Pubitemid 23218315)
82. Schnarr B, Ezernieks J, Sebald W, Duschl A: IL-4 receptor complexes containing or lacking the gamma C chain are inhibited by an overlapping set of antagonistic IL-4 mutant proteins. Int Immunol 1997;9:861-868. (Pubitemid 27231965)